SBRI Healthcare's NHS Cancer Programme Open Call 4: Is Your Company Eligible?

SBRI Healthcare's NHS Cancer Programme Innovation Open Call 4 opens for applications on 14 October 2026 and closes on 1 December 2026 at 1pm GMT. It offers up to £3 million per project through a Real-World Implementation & Evaluation Fund, but it is not an entry point for early-stage research: applicants need regulatory approval and prospective real-world evidence already in hand before they apply.

What SBRI Healthcare usually funds, and why this call is different

SBRI Healthcare is the NHS's Small Business Research Initiative for healthcare, funded by NHS England's Accelerated Access Collaborative and delivered with the Health Innovation Network. Its standard route is a two-phase model: Phase 1 offers up to £100,000 over six months for feasibility testing, and successful Phase 1 projects can be invited to apply for Phase 2, worth up to £800,000 over 12 months for prototype development and early clinical evidence. You cannot apply to Phase 2 directly; it follows a successful Phase 1 award.

NHS Cancer Programme Innovation Open Call 4 sits outside that pathway entirely. It is a much larger, later-stage competition aimed at innovations that already have regulatory approval and real-world evidence, and that need funding to scale into NHS cancer pathways rather than to prove feasibility. If your project is still at proof-of-concept or early clinical evidence stage, this specific call is not for you; the standard Phase 1 route, when it next opens, is the better fit.

Inside Call 4: two funding streams, two different applicants

The competition addresses two challenges within NHS cancer care: improving productivity and capacity on cancer pathways to support the NHS in meeting all Cancer Waiting Time standards by March 2029, and driving earlier detection and diagnosis of cancer through novel screening, prompt presentation, case-finding or diagnostic tools. It funds that work through two distinct streams with different lead applicants.

That second column matters more than it looks. If you're a company reading this, the Real-World Implementation & Evaluation Fund is the stream you'd lead. The Innovation Spread Fund is restricted to Integrated Care Boards and Cancer Alliances as lead applicants, with a maximum of one application per Cancer Alliance region, so a company can only take part as a named technology partner within someone else's bid, not as the applicant.

Key dates

• Competition announced: 1 June 2026
• Briefing webinar: 18 June 2026
• Matchmaking form deadline: 24 June 2026, 11pm
• Application portal opens: 14 October 2026
• Application deadline: 1 December 2026, 1pm GMT
• Contracts expected to start: no later than 30 April 2027

With the portal not opening until 14 October, there is time to line up an evaluation partner and NHS relationships properly rather than scrambling once applications go live. That six-week run-up between portal opening and deadline is short by SBRI Healthcare standards for a competition of this size, so the preparation work needs to happen now, not once the forms go live.

Who is actually eligible, and who isn't

The Real-World Implementation & Evaluation Fund has a maturity threshold that rules out a lot of otherwise-strong innovations. To apply, you need either a CE mark (or equivalent regulatory approval) for the intended cancer use, or an application already submitted with approval expected before peer review, plus evidence of safety and clinical utility from prospective use in at least one live healthcare setting. SBRI Healthcare states explicitly that the competition is not intended to fund early-stage research, biomarker development, proof-of-concept studies or the generation of initial clinical evidence.

On company type, the fund is broader than it might first appear: SMEs, large corporates, registered charities (applying via a trading subsidiary), universities with a credible route to commercial and NHS spread, ICBs and NHS Trusts can all lead. Non-UK or non-EU organisations cannot lead an application but can participate as subcontractors if they bring expertise the consortium genuinely needs. Every project must show a clear health benefit to the UK, and implementation must happen in NHS settings in England, no exceptions.

The NHS partnership and independent evaluation partner, in practice

Two relationships are mandatory for the Real-World Implementation & Evaluation Fund: a partnership with at least one NHS organisation, and an independent evaluation partner with no financial interest in the innovation being assessed. Cancer Alliance involvement is strongly encouraged but not required for this stream specifically.

The independent evaluation partner doesn't have to be UK-based, but it does need demonstrable expertise in health technology assessment, implementation science or real-world evidence generation. SBRI Healthcare's own guidance points to prospective, real-world data as the strongest evidence base, rather than retrospective analysis or proof-of-concept results, and expects patient and public involvement to run throughout delivery, not just at the design stage.

What strengthens an application

Beyond meeting the maturity threshold, SBRI Healthcare's guidance points to a handful of factors that separate genuinely competitive bids. Prospective real-world data carries more weight than retrospective analysis or proof-of-concept results. Early engagement with Cancer Alliances and local NHS trusts, ideally with a named contact you've already discussed feasibility with, strengthens the case even where it isn't formally required.

Implementation planning needs to account realistically for onboarding, information governance and regulatory timelines inside NHS organisations, which routinely run longer than applicants expect. For rarer cancers, the panel accepts that traditional outcome metrics may not apply and expects applicants to propose appropriate alternatives rather than force-fitting standard measures. On cost, assessors weigh value for money directly: overhead claims need to be realistic, not maximised.

Should your company apply?

Honestly, most early-stage R&D companies shouldn't, not because the opportunity isn't real, but because the maturity bar is set deliberately high. This call is built for innovations that have already cleared regulatory approval and generated prospective clinical evidence, and that now need funding to get from one NHS site to many.

If that's genuinely where your project is, up to £3 million with a clear NHS route is a serious opportunity worth the application effort. If you're still validating clinical utility or waiting on regulatory approval, applying here is likely to cost you weeks of work for a proposal that won't pass initial screening, and you'd be better served watching for the next standard SBRI Healthcare Phase 1 round instead. Neither outcome reflects badly on the underlying innovation; it reflects where this particular fund has drawn its line, and that line is worth reading carefully before committing the weeks a proposal like this genuinely takes.

How GrantHero helps

This is exactly the judgement call GrantHero exists to help with: telling you honestly whether a competition is worth your time before you commit weeks to an application, not just surfacing every open call regardless of fit. Our Discovery tier runs eligibility fit checks against competitions like this one, and if it's a genuine match, our expert-supported plans pair AI-assisted drafting with a specialist grant reviewer who has seen what NHS assessment panels actually look for. Browse the wider set of live and recent competitions we cover in our competition guides, or see how we support healthcare and life sciences companies specifically.